| Orexigen Therapeutics announced that on November 18, the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program. The stock option is intended to be an incentive stock option to the extent permitted by law and has an exercise price per share equal to $7.52, the fair market value on the grant date. :theflyonthewall.com |
